我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
1
1 进行中
药物批准
11
批准总数
监管机构
2
监管机构数
成立时间
N/A
暂无试验阶段数据
进行中（未招募）
100.0%
NMPA
National Medical Products Administration
FDA
Food and Drug Administration
10
- Tabuk Pharmaceutical Manufacturing Company has launched Vibativ (telavancin) injection in Saudi Arabia through an exclusive partnership with Cumberland Pharmaceuticals, targeting hospital-acquired pneumonia and serious skin infections. - The FDA-approved antibiotic is specifically designed to combat multidrug-resistant Gram-positive bacteria, including MRSA and MSSA, with studies showing it maintains potency against resistant strains over 10 years after introduction. - Vibativ demonstrated significantly higher cure rates compared to vancomycin in clinical trials for hospital-acquired and ventilator-associated bacterial pneumonia, offering once-daily dosing without therapeutic drug monitoring requirements. - The launch addresses the urgent global health crisis of antimicrobial resistance, providing physicians in the Middle East with a powerful tool against difficult-to-treat bacterial infections.
